The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective against severe COVID-19 beginning 28 days post-vaccination, according to…
Study includes more than 2,700 healthcare workers in Delhi, India, who were symptomatic and underwent RT-PCR testing for COVID-19. Findings suggest 50% vaccine effectiveness against…
Study of 621 people in the UK with mild COVID-19 infections found that people who received two vaccine doses could still pass the infection on…
First global estimates of impact of the COVID-19 pandemic on mental health in 2020 suggests additional 53 million cases of major depressive disorder and 76…
Researchers compared data from the US National Vital Statistics System (NVSS) to three non-governmental, open-source databases on fatal police violence and found that NVSS under-reported…
Study is most comprehensive of its kind and included more than 70,000 adults in the UK hospitalized with severe COVID-19 disease. Of these, half (36,367…
An observational study of patients in London hospitals suggests that the B.1.1.7. variant is not associated with more severe illness and death, but appears to…
First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease,…
Phase 2 randomized controlled trial of a recombinant adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine) was conducted in China in April 2020 and involved more…
First review of all available evidence including 172 observational studies looking at how physical distancing, face masks, and eye protection affect the spread of COVID-19,…
Retraction: This article has been retracted by 3 of its 4 authors after they were unable to independently verify their data. A large observational study…
First evidence that early treatment with triple antiviral therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin — alongside standard care — is safe and shortens duration…